Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
“With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.
President Donald Trump's nominee for FDA commissioner, Dr. Heidi Overton, is set to testify before the Senate health committee on Thursday. Lawmakers are expected to scrutinize her stance on vaccines, the abortion pill and other FDA-regulated products facing new scrutiny. Overton, a physician and former White House staffer, has a history of advocating positions that diverge from the FDA's usual policies.
Her support for separating childhood vaccines, opposition to expanding access to mifepristone and criticism of the FDA's decision to allow mail delivery of the abortion pill have raised concerns among some lawmakers.
Written by urgent.news from Winnipeg Free Press's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Senators to question FDA nominee about her views on abortion pill and vaccines winnipegfreepress.com
